Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines, formerly known as BeiGene, reported a strong financial position with US$2.6 billion in cash at the end of 2024, which positions the company well for future growth and investment in its research and development. The company's flagship drug, Brukinsa, generated sales of US$2.6 billion in 2024, reflecting a remarkable year-over-year increase of 105%, indicating significant market acceptance and capturing over 68% of total sales. Additionally, BeOne's overall revenue forecasts have been raised for the coming years, bolstered by strong sales momentum for Brukinsa and Tevimbra, which demonstrated a solid performance against competitors, thereby enhancing the company's market share and solidifying its competitive positioning in the oncology therapeutics market.

Bears say

BeiGene's financial outlook remains concerning due to a significant decline in cash flow from operations, with fourth-quarter cash flow falling to US$75 million from US$188 million in the previous quarter, primarily driven by increased receivables and inventory. The company is experiencing substantial net losses, reported at US$645 million for the period, despite a narrowing of losses by 27% year-over-year, indicating ongoing financial challenges. Furthermore, downward revisions in revenue projections for key products, including a reduction in peak sales estimates for Tevimbra and ociperlimab, highlight increased uncertainty and risk to BeiGene's future profitability.

BeiGene Ltd (ONC) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 3 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $320.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $320.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.